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No studies have examined the transplantation of a bone marrow aspirate (BMA) containing mesenchymal stem cells (MSCs)
combined with human parathyroid hormone 1-34 (hPTH1-34) administration. Therefore, we evaluated the feasibility and efficacy
of autologous BMA transplantation combined with hPHT1-34 administration in a bone necrosis model. The metatarsal bones
of rabbits were necrotized using liquid nitrogen, and the rabbits received a BMA transplantation or saline injection followed by
hPTH1-34 (30 𝜇g/kg) or saline administration three times per week (𝑛 = 3-4 per group). The rabbits were euthanized at 12 weeks
after the initiation of treatment. No systemic adverse effects or local neoplastic lesions were observed. Importantly, the rabbits in
the BMA transplantation plus hPTH1-34 group showed the highest bone volumes and histological scores of new bone. These data
confirmed the feasibility of BMA transplantation combined with hPTH1-34, at least during the experimental period. The observed
efficacymay be explained by a synergistic effect from the stimulation ofMSCdifferentiation to osteoblasts with hPTH1-34-mediated
suppression of apoptosis in osteoblasts. These results indicate the promising potential for BMA transplantation combined with
hPTH1-34 administration in bone necrosis treatment. Longer term experiments are needed to confirm the safety of this therapeutic
strategy.
1. Introduction
Osteonecrosis (ON), which involves the physiological remo-
deling of bone tissues [1], is thought to be caused by inter-
ruptions in blood flow, a decline in the function/number of
osteoprogenitor cells, and apoptosis of the osteocytes [2–10].
Under physiological conditions, bone formation and bone
resorption are coupled, and the balance between these two
processes is maintained appropriately. However, in necrotic
lesions, this balance is destroyed, and themechanical strength
of the bone is weakened. ON typically develops in the hip,
knee, shoulder, ankle joint, and carpal bones. The collapse
and deformity of the necrotized tissue can cause pain or
functional impairment and may lead to the development of
osteoarthritis, necessitating joint replacement or arthrodesis.
However, joint replacements for the hip, knee, shoulder,
and ankle are associated with durability issues and the risk
of various complications such as infection or thromboem-
bolism. In addition, although arthrodesis for the carpal bones
can alleviate pain, this may result in compromised joint
function. Therefore, these treatments are not recommended
for younger individuals. ON develops frequently in highly
active patients when they reach 30–40 years of age as a
complication associated with the use of corticosteroids [11].
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Thus, it is necessary to develop appropriate treatments for
preserving bone that can regenerate necrotized bone and
enhance bone strength.
Core decompression [12], autologous bone grafts [13, 14],
and bone marrow aspirate (BMA) transplantation [15–18]
have been performed in an attempt to regenerate necrotized
bone. Core decompression is a method designed to improve
blood flow into a necrotized lesion and aid the inflow of
precursor cells or growth factors from normal tissues via
communication between the necrotized lesion and normal
tissues. Autologous bone graft and BMA transplantation
simultaneously stimulate bone formation by providing the
required components.
The ability to form new bone via BMA transplantation
has been confirmed in basic experiments [1] and is thought to
depend on mesenchymal stem cells (MSCs) or osteoprogen-
itor cells. The bone marrow is a source of MSCs, which have
the potential to differentiate intomesenchymal tissues such as
bone, cartilage, and fat [19]. Autologous MSCs derived from
bone marrow have been found to directly differentiate into
osteoblasts and contribute to bone regeneration in a rabbit
experimental model of ON [20]. Furthermore, a prospective
controlled clinical study showed better results in the group
receiving bone marrow cell implantation than in that receiv-
ing core decompression alone [21]. However, cell therapy is
complicated by the lack of mechanical strength at early stages
after transplantation. Consequently, patients are at risk of
collapse and must avoid mechanical load for a prolonged
time. Thus, new strategies to ensure mechanical strength at
early stages after transplantation with active osteogenesis at
the necrotic site are required.
Human parathyroid hormone (hPTH) 1-34 has been
shown to stimulate bone formation and is therefore widely
used for the clinical treatment of osteoporosis. Moreover,
intermittent administration of hPTH1-34 stimulates the dif-
ferentiation of osteoprogenitor cells into osteoblasts [22, 23]
and suppresses apoptosis in osteoblasts [24], thereby pro-
moting bone formation. Since the BMA contains MSCs
or osteoprecursor cells with bone differentiation capability,
theoretically, the concomitant use of hPTH 1-34 may stimu-
late active osteogenesis at an early stage after BMA transplan-
tation. However, the application of such a technique may be
limited, asMSCs have been shown to be tumorigenic [25, 26].
In addition, osteosarcomas have been shown to develop in
basic experiments with hPTH1-34, and a safety threshold for
its use has been suggested [27]. However, to the best of our
knowledge, no reports have described the concomitant use
of these two methods.
In this study, we evaluated the safety and efficacy of
the concomitant use of BMA transplantation and hPTH1-34
administration in the early treatment period using a rabbit
model of necrotized small bone [1].
2. Materials and Methods
2.1. ONModel. Ten 12-week-old Japanese white rabbits (body
weight 2.5–3 kg) were used in this study. All protocols
involving animals were approved by the institutional review
board for animal testing of Tsukuba University. The animals
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Figure 1: Experimental groups examined in the present study.
were anesthetized with intramuscular administration of
ketamine (50mg/kg body weight) and xylazine (14mg/kg
body weight). The ON model was established as previously
described with confirmation of severe osteonecrotic changes
that persisted throughout 20 weeks [1]. Skin incisions of
approximately 3 cm were made on the lateral side of the foot,
and the fourth metatarsal bone was exposed and carefully
removed after the attached ligaments and joint capsule were
dissected. The bone was then soaked in liquid nitrogen for
5min. After the bone was returned to room temperature, a
bone tunnel was prepared with a 2mm drill. An 18-G injec-
tion needle was used in the bone tunnel to implant 1 mL bone
marrow or saline.The bonewas embedded into subcutaneous
pockets that had been prepared at two locations on the right
cranial posterior and the left caudal posterior sides. The
needle was then removed and the skin was sutured.
2.2. Preparation of hPTH1-34. hPTH1-34 was synthesized by
Asahi Kasei Corporation (Tokyo, Japan). The hormone stock
solution was dissolved at 30 𝜇g/mL in physiological saline
containing 0.1% rabbit serum albumin.
2.3. Experimental Protocol. The rabbits were divided into
two groups, with five rabbits per group. In the first group,
rabbits were injected subcutaneously with 30 𝜇g/kg hPTH1-
34 three times per week. Rabbits in the second group were
injected with saline three times per week. For each rabbit,
the metatarsal bones on one side were injected with 1mL
bone marrow collected from the iliac crest; the bones on the
other side were injected with saline only (Figure 1). Twelve
weeks later, the rabbits were sacrificed via administration
of excessive pentobarbital, and samples were collected. Cal-
cein (8mg/kg) for fluorescent labeling was subcutaneously
administered at 2 and 9 days prior to euthanasia.
2.4. Safety Evaluation. The body weight of each rabbit was
measured once aweek. At the start and end of the experiment,
5mL peripheral blood was collected to measure alkaline
phosphatase (ALP), calcium (Ca), and inositol phosphate
(IP) levels. The extracted metatarsal bones were fixed with
4% paraformaldehyde and divided into halves, one of which
was demineralized with ethylenediaminetetraacetic acid dis-
odium salt for 4 weeks and then embedded in paraffin. A
thin slice (5 𝜇m) was taken near the divided surface, and the
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Figure 2: Photomicrograph of an 8mm long metatarsal bone covered by white fibrous tissue on the surface.
development of neoplastic lesions was evaluated in samples
dyed with hematoxylin and eosin. All samples were evaluated
by a pathology expert.
2.5. Efficacy Evaluation. Osteocalcin was measured in the
collected blood. Before halving the metatarsal bones, micro-
computed tomography images were taken (𝑛 = 3 per group).
The data were imported into Mimics (Materialis, Leuven,
Belgium), the threshold was set for the computed tomo-
graphic value for drawing the bones, and the volume was
determined. Histologically, bone formation was qualitatively
evaluated from the demineralized samples that were prepared
as described above. The other half of the sample was embed-
ded in glycidyl methacrylate to create a nondemineralized
sample. A thin slice (5 𝜇m) was taken near the divided
surface and dyed with toluidine blue. Calcein labeling was
visualized using a fluorescent microscope. Five randomly
selected 100x bright and dark fields were captured, and the
labeled surface/bone surface ratio (LS/BS) was measured
from the two merged images.
2.6. Statistical Analysis. Comparisons between groups were
carried out by Student’s t-tests. Differences with 𝑃 values less
than 0.05 were considered statistically significant.
3. Results
One rabbit that developed an infection and two rabbits
whosemetatarsal bones were identified only on one side were
excluded from further analysis. A total of 14 samples were
collected from seven rabbits (BMA plus hPTH1-34: 𝑛 = 3;
no BMA plus hPTH1-34: 𝑛 = 3; BMA plus saline: 𝑛 = 4; no
BMA plus saline: 𝑛 = 4).
The metatarsal bones that were removed in all groups
maintained their original form and were surrounded by
white fibrous tissues. No apparent proliferating tissues were
observed (Figure 2).
3.1. Safety Evaluation. The body weight of the rabbits tem-
porarily decreased after surgery in all groups but gradu-
ally increased thereafter (Figure 3). No differences in body
weights were observed between the groups. In addition, there
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Figure 3: Body weight of rabbits at the time of surgery and at the
end of the 12-week experimental period.
were no differences in Ca, IP, or ALP levels in the blood
(Table 1). Neoplastic lesions were not observed.
3.2. Efficacy Evaluation. Preoperative osteocalcin levels did
not significantly differ between rabbits treated with hPTH1-
34 (42.3 ± 10.8 ng/mL) and those treated with saline (33.4 ±
13.2 ng/mL); however, the osteocalcin levels at the end of
the experiment were significantly higher in rabbits treated
with hPTH1-34 (99.4 ± 59.7 ng/mL) than in rabbits treated
with saline (16.3 ± 6.5 ng/mL, Figure 4). Histological analysis
revealed that the metatarsal bones were filled with fibrous
tissue in both groups and that blood vessels had formed (Fig-
ure 5). Cancellous bones showed a mixture of osteonecrotic
changes, including empty lacunae and a fibrous marrow
cavity, along with bone tissue consisting of osteocyte-filled
lacunae. Arrays of osteoblasts and osteoclast-like cells were
observed on the surface of the new bone. In histomorpho-
logical analysis, fluorescent labeling was observed in the dark
fields in all samples (Figure 6). Both the LS/BS ratios and bone
volume measurements were highest in rabbits who received
the combination of BMA transplantation and hPTH1-34
(Figures 7 and 8).
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Table 1: Blood examination at the start and end of the experiment in groups with and without hPTH1-34 administration.
hPTH1-34, pre Saline, pre hPTH1-34, post Saline, post
Ca (mg/dL) 12.92 ± 0.19 13 ± 0.32 13.2 ± 0.34 12.9 ± 0.22
IP (mg/dL) 8.2 ± 1.01 7.94 ± 0.49 4.72 ± 0.42 4.92 ± 0.23
ALP (IU/L) 361.8 ± 67.48 441.2 ± 49.38 167.4 ± 24.25 179.2 ± 48.77
ALP, alkaline phosphatase; Ca, calcium; IP, inositol phosphate; post: end of the experiment; pre: at the time of surgery.
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Figure 4: Blood osteocalcin levels. Pre: before surgery; Post: at the
end of the 12-week experimental period. ∗𝑃 < 0.05.
4. Discussion
In this study, we investigated the safety and efficacy of BMA
transplantation combined with hPTH1-34 administration in
the early treatment period. Our results demonstrated that the
combined treatmentwas safe during the experimental period,
without induction of necrotic lesions, tumors, or weight loss
in any of the rabbits. Moreover, bone volume increased in
the rabbits treated with BMA transplantation plus hPTH1-34.
Therefore, this combination can be considered as a potential
treatment for bone regeneration.
Efficacy was confirmed in terms of the systemic drug
potency, as indicated by a significant increase in serum osteo-
calcin levels in the rabbits receiving hPTH1-34. Moreover, in
the histomorphological measurements and microcomputed
tomography results, numerical values were highest in the
rabbits treated with hPTH1-34 and BMA transplantation.
Vascularization was observed inside the metatarsal bones. It
is possible that hPTH1-34 induced these effects owing to its
ability to directly stimulate MSC differentiation [22, 23] and
suppress the apoptosis of osteoblasts [24]. However, further
studies are needed to examine the specific mechanisms
involved.
MSCs have been shown to stimulate the metastatic capa-
city of malignant cells in animal breast cancer models [28];
however, no reports have described the development of
new cancer in noncancerous tissue in response to MSC
transplantation. Hernigou et al. [25] conducted magnetic
resonance imaging follow-up examinations of 1,873 cases in
which MSCs derived from the BMA were transplanted and
reported no tumors in the location of the transplantation.
Therefore, the use of a BMA containing MSCs may be a safe
option for the induction of bone regeneration.
hPTH1-34 is known to stimulate osteogenesis and is
widely used in clinical settings. However, during the devel-
opment phase of the treatment, osteosarcomas have been
reported to develop in rats treated with hPTH1-34. Impor-
tantly, the incidence of osteosarcoma is reported to be
dependent on the dose of the drug and the administration
period [27]. Although a safe dose range has been established
for human use, the administration period is restricted to 18
months, and administration to patients at risk of developing
osteosarcoma is prohibited. In the present study, systemic
effects were evaluated by monitoring body weight and blood
biochemistry parameters indicative of osteosarcoma, and
local effects were assessed via histology. No differences
were found in body weight or serum levels of Ca, IP, or
ALP, and no adverse systemic effects were observed. The
decrease observed in serum IP and ALP levels may have
been caused by physiological bone maturation, since only
immature rabbitswere used in this study.However, therewere
no significant differences between the hPTH1-34- and saline-
treated groups observed in serum ALP levels, an important
marker for the diagnosis of osteosarcoma [29, 30]. Moreover,
no histological development of neoplastic lesions was noted.
These results indicate the feasibility and possible safety of the
present treatment, at least in the early period. However, Vahle
et al. [31] reported that the formation of bone neoplasms
depended on the duration and doses of the treatment and
occurred in rats treated for 20 or 24months.Therefore, longer
term experiments are needed to fully investigate the safety of
the present treatment.
There are some limitations to this study. First, the number
of animals was very small for reliable statistical consider-
ation of efficacy. Second, mechanical evaluations were not
performed. Third, certain properties such as the number of
MSCs or the variety of cells in the transplanted BMA were
not analyzed. Fourth, we could not investigate the state of
bone resorption because we did not use any bone resorption
markers. Therefore, more detailed studies are needed to
determine the optimal number ofMSCs, timing of treatment,
and interval and frequency of hPTH1-34 administration for
achieving proper bone regeneration.
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Figure 5: Hematoxylin and eosin staining of bone tissues from all groups (12.5x and 100x). EL, empty lacunae; OFL, osteocyte-filled lacunae.
The arrows indicate osteoclasts. The arrowheads indicated osteoblasts. The empty arrows indicate blood vessels.
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Figure 6: Fluorescent labeling of tissues in each group.
5. Conclusion
In our novel ON model, we established a new bone regen-
erative strategy that involves the synergistic effects from
the concomitant use of local BMA transplantation and
systemic hPTH administration. The safety and efficacy of
this concomitant therapy were confirmed at the early stage
of treatment. Although additional studies are still required
to validate these findings, these preliminary results show
promise of this strategy for clinical applications.
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Figure 8: Bone volume measurements by microcomputed tomog-
raphy.
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